Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAGM.L Regulatory News (AGM)

  • There is currently no data for AGM

Board Changes

29 Jun 2018 10:19

RNS Number : 0590T
Applied Graphene Materials PLC
29 June 2018
 

 

 

29th June 2018

 

Applied Graphene Materials plc

 

("Applied Graphene Materials", "the Group", "the Company" or "AGM")

 

Board Changes

 

Applied Graphene Materials, the producer of specialty graphene materials, is pleased to announce that it intends to appoint Dr. Hugh Adrian Potts (Adrian), aged 57, to the Board as the Group's new Chief Executive Officer, following the announcement earlier in the year of the retirement of current CEO Jon Mabbitt.

 

Adrian has been Vice President for Business Development at AGM since January 2015. In this role he was responsible for leading the company's business development strategy in the U.S. Adrian previously worked at Cytec Process Materials in roles including Global Business Development Director, President of Cytec Process Materials, CA Inc. and President of Umeco Structural Materials Inc.

 

In addition, the Board announces that Gareth Jones, Chief Financial Officer, has given notice of his resignation. The Board's recruitment process to appoint a successor will commence immediately and an announcement will follow in due course. Gareth will remain with the Company beyond the announcement of AGM's annual results to ensure a smooth handover to his successor.

 

Dr. Bryan Dobson, Non-Executive Chairman of AGM, commented:

 

"We are delighted that Adrian has agreed to take on the role of CEO. He already has an in-depth understanding of AGM's unique offer and strategy and has the skills to take the Group to the next level. On behalf of the Board, I would like to thank Gareth Jones for his contribution during his time at AGM and wish him all the best in his future career."

 

A further announcement will be made on commencement of Adrian Pott's appointment setting out the additional required disclosures pursuant to Rule 17 and Schedule 2 (g) of the AIM Rules for Companies.

 

Ends

 

 

For further information, please contact:

 

N+1 Singer +44 (0) 207 496 3000

Richard Lindley / James White

 

Hudson Sandler +44 (0) 207 796 4133

Charlie Jack / Emily Dillon

Notes to Editors

Applied Graphene Materials was founded by Professor Karl Coleman in 2010 with its operations and processes based on technology that he initially developed at Durham University. The Group is based at the Wilton Site on Teesside and was admitted to AIM in November 2013.

The Group has developed proprietary bottom-up processes which are capable of producing high purity graphene nanoplatelets using a continuous process. The manufacturing processes are based on sustainable, readily available raw materials and therefore do not rely on the supply of graphite, unlike a number of other graphene production techniques. Applied Graphene Materials owns the intellectual property and know-how behind these processes.

Applied Graphene Materials works in partnership with its customers using its knowledge and expertise to provide bespoke graphene dispersions and formats to deliver enhancements and benefits for a wide range of applications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAEANKNAFPPEEF
Date   Source Headline
25th Apr 20187:00 amRNSIssue of share options to Directors
18th Apr 20188:41 amRNSHolding(s) in Company
10th Apr 20187:00 amRNSInterim Results
8th Mar 20187:00 amRNSCollaboration with SHD and Magna Exteriors
1st Feb 20187:00 amRNSBoard Change
15th Jan 20189:22 amRNSHolding(s) in Company
10th Jan 20185:30 pmRNSHolding(s) in Company
10th Jan 20184:40 pmRNSSecond Price Monitoring Extn
10th Jan 20184:35 pmRNSPrice Monitoring Extension
8th Jan 20181:21 pmRNSHolding(s) in Company
4th Jan 20187:00 amRNSResult of AGM
3rd Jan 20187:00 amRNSAGM Statement
12th Dec 20177:00 amRNSNotice of AGM
7th Nov 20179:47 amRNSHolding(s) in Company
2nd Nov 20177:00 amRNSDirector/PDMR Shareholding
30th Oct 20171:15 pmRNSResults of Open Offer and General Meeting
12th Oct 20175:19 pmRNSPosting of Circular and Notice of General Meeting
10th Oct 20176:16 pmRNSFurther Details on the Fundraising
10th Oct 201711:41 amRNSClose of Accelerated Bookbuild
10th Oct 201711:00 amRNSPrice Monitoring Extension
10th Oct 20177:05 amRNSProposed Placing by Accelerated Bookbuild
10th Oct 20177:00 amRNSPreliminary Results
22nd Aug 20177:00 amRNSInvestor Site Visit
24th May 20177:00 amRNSNew Graphene Delivery Technology & Trading Update
22nd May 20174:18 pmRNSIssue of Equity and Total Voting Rights
26th Apr 20174:35 pmRNSPrice Monitoring Extension
11th Apr 20177:00 amRNSInterim Results
7th Apr 20174:40 pmRNSSecond Price Monitoring Extn
7th Apr 20174:35 pmRNSPrice Monitoring Extension
5th Apr 20174:40 pmRNSSecond Price Monitoring Extn
5th Apr 20174:35 pmRNSPrice Monitoring Extension
1st Feb 20177:00 amRNSGrant of Options
30th Jan 20177:00 amRNSShare Purchase by CFO-Designate
25th Jan 20177:00 amRNSBoard & Operational Appointments
20th Dec 20167:00 amRNSAGM Statement
31st Oct 20167:01 amRNSDirector/PDMR Shareholding
31st Oct 20167:00 amRNSDirectorate Change
17th Oct 20167:00 amRNSFinal Results
14th Oct 20167:00 amRNSFirst Production Order
12th Aug 20167:38 amRNSExercise of Share Options and PDMR Dealing
12th Aug 20167:00 amRNSDirectorate Change
12th Aug 20167:00 amRNSPeriod end trading update and notice of results
8th Aug 20167:00 amRNSProduct Development and New JDA
23rd Mar 20167:00 amRNSInterim Results
26th Jan 20163:21 pmRNSHolding(s) in Company
26th Jan 201612:15 pmRNSResult of AGM
25th Jan 20167:00 amRNSAGM Statement
22nd Jan 201610:33 amRNSHolding(s) in Company
13th Jan 20169:08 amRNSHolding(s) in Company
11th Jan 20163:42 pmRNSIssue of share options to Directors

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.